Publications by authors named "L Don"

Article Synopsis
  • T cell-based immunotherapies are effective against cancer but are limited by cancer cells' ability to escape immune detection; recent research is shifting focus to natural killer (NK) cells, which can target tumors directly.
  • Newly developed methods have been used to screen for compounds that improve NK cell functionality, particularly in dysfunctional cells found in the tumor microenvironment.
  • A promising compound, a C
View Article and Find Full Text PDF
Article Synopsis
  • Hypersialylation, an increase in sialic acids on glycans, is common in cancer cells and helps them evade the immune system by interacting with Siglec receptors on immune cells.
  • In lung cancer patients and tumor models, myeloid-derived suppressor cells (MDSCs) are highly sialylated and express inhibitory Siglec receptors, which can hinder T-cell activity.
  • Blocking Siglec receptors or removing sialic acids from MDSCs impairs their immune suppression, highlighting the role of CCL2 in this process and suggesting that targeting these interactions could boost anticancer immunity.
View Article and Find Full Text PDF

Tumor-specific T cells are frequently exhausted by chronic antigenic stimulation. We here report on a human antigen-specific ex vivo model to explore new therapeutic options for T cell immunotherapies. T cells generated with this model resemble tumor-infiltrating exhausted T cells on a phenotypic and transcriptional level.

View Article and Find Full Text PDF

Background: Newborns commonly experience pain due to a variety of reasons. Non-nutritive sucking (NNS) is thought to be an effective non-pharmacological method of pain-relief. However, the significant heterogeneity in some systematic reviews limited the certainty of the findings about NNS.

View Article and Find Full Text PDF

Inflammatory bowel diseases (IBDs) are a set of complex and debilitating diseases for which there is no satisfactory treatment. Recent studies have shown that small peptides show promise for reducing inflammation in models of IBD. However, these small peptides are likely to be unstable and rapidly cleared from the circulation, and therefore, if not modified for better stability, represent non-viable drug leads.

View Article and Find Full Text PDF